DexCom (DXCM) Intrinsic Value Calculator

Updated: Nov 22, 2026

DexCom (DXCM) trades at $79.32, close to its base-case intrinsic value of $78.25 (-1%). The model starts from $3.13 in expected earnings per share, grows it at 16.1% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 25.0x exit multiple, and discounts the result back at 10% per year. The stock looks roughly fairly priced under these assumptions — the sliders below show how sensitive that conclusion is to growth and discount-rate changes.

Overvalued by 1.3%
Current Price
$79.32
Intrinsic Value
$78.25
Implied Upside: -1.3%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 16.1%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 25.0x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$78.25
--
Tradestie Long-Horizon Cycle Intelligence (2009–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (17-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Surgical & Medical Instruments & Apparatus • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Surgical & Medical Instruments & Apparatus, only 23.2% of peer companies at >$1B revenue scale (496 historical 5-year windows; industry median CAGR: 5.5%/yr) sustained ≥10%/yr 5-year compound revenue growth (broad >$1B equity base rate: 24.5%).

≥5%/yr (5Y)
55.2%
All >$1B: 50.1%
≥10%/yr (5Y)
23.2%
All >$1B: 24.5%
≥15%/yr (5Y)
7.3%
All >$1B: 12.2%
≥20%/yr (5Y)
3.2%
All >$1B: 6.8%
≥25%/yr (5Y)
1.4%
All >$1B: 4.2%
≥30%/yr (5Y)
0.4%
All >$1B: 2.4%
17-Yr Revenue Scale
$30M → $4.66B
16Y CAGR: +37.2%/yr • 5Y: +19.3%
2008–2009 Cycle Trough Floor
-154.4% Op Margin
FY2009 Rev: $30M
2022 Rate-Shock Floor
13.4% Op Margin
FY2022 Rev: $2.91B (+18.8% YoY)
Latest vs Cycle Median Margin
19.6% vs -8.3% med
Cyclical Margin Profile — Stress-Test Exit Multiples
Multi-Cycle Revenue & Operating Margin Trajectory (2009–2025) Expansion 2008–09 / 2022 Macro Stress
-154%
'09
-93%
'10
-59%
'11
-56%
'12
-18%
'13
-8%
'14
-14%
'15
-11%
'16
-6%
'17
-18%
'18
10%
'19
16%
'20
11%
'21
13%
'22
17%
'23
15%
'24
20%
'25
Inspect All 17 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $4.66B +15.6% $912M 19.6% Standard
FY2024 (2024-12) $4.03B +11.3% $600M 14.9% Standard
FY2023 (2023-12) $3.62B +24.5% $598M 16.5% Standard
FY2022 (2022-12) $2.91B +18.8% $391M 13.4% 2022 Rate Shock
FY2021 (2021-12) $2.45B +27.1% $266M 10.9% Standard
FY2020 (2020-12) $1.93B +30.5% $300M 15.5% Standard
FY2019 (2019-12) $1.48B +43.1% $142M 9.6% Standard
FY2018 (2018-12) $1.03B +43.6% -$186M -18.1% Standard
FY2017 (2017-12) $718M +25.3% -$42M -5.9% Standard
FY2016 (2016-12) $573M +42.6% -$64M -11.1% Standard
FY2015 (2015-12) $402M +55.1% -$57M -14.2% Standard
FY2014 (2014-12) $259M +62.0% -$22M -8.3% Standard
FY2013 (2013-12) $160M +60.2% -$29M -18.1% Standard
FY2012 (2012-12) $100M +30.9% -$56M -55.8% Standard
FY2011 (2011-12) $76M +57.0% -$45M -58.7% Standard
FY2010 (2010-12) $49M +63.7% -$45M -93.2% Standard
FY2009 (2009-12) $30M — -$46M -154.4% 2008–09 Trough Floor

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM Valuation Scenarios: Simulated 5-Day Put-Wall Income & Directional Payoffs

Compare $8,161 for 100 DXCM shares against defined-margin put credit buffers and 5-day directional option spreads.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $85 / $75 Bear Put Spread

Buy 1x $85P · Sell 1x $75P · 31d

Net Entry $380 Debit
T+5d @ -5% Drop +$186 (+49%)
Max Risk / Buffer $380 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Model Inputs
Base EPS $3.13
Current Price $79.32
Historical PE 25.0x
Analyst Growth Est. 16.1%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).